CASI Pharmaceuticals Inc. (NASDAQ:CASI) went up by 0.27% from its latest closing price compared to the recent 1-year high of $3.90. The company’s stock price has collected 0.16% of gains in the last five trading sessions. Press Release reported on 01/03/22 that CASI PHARMACEUTICALS, RECEIVES NASDAQ DEFICIENCY NOTICE
Is It Worth Investing in CASI Pharmaceuticals Inc. (NASDAQ :CASI) Right Now?
Plus, the 36-month beta value for CASI is at 0.34. Opinions of the stock are interesting as 4 analysts out of 4 who provided ratings for CASI Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $4.45, which is $3.68 above the current price. CASI currently public float of 105.64M and currently shorts hold a 2.01% ratio of that float. Today, the average trading volume of CASI was 1.21M shares.
CASI’s Market Performance
CASI stocks went up by 0.16% for the week, with a monthly drop of -4.98% and a quarterly performance of -34.44%, while its annual performance rate touched -76.96%. The volatility ratio for the week stands at 7.79% while the volatility levels for the past 30 days are set at 7.81% for CASI Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -5.87% for CASI stocks with a simple moving average of -42.10% for the last 200 days.
Analysts’ Opinion of CASI
Many brokerage firms have already submitted their reports for CASI stocks, with BTIG Research repeating the rating for CASI by listing it as a “Buy.” The predicted price for CASI in the upcoming period, according to BTIG Research is $4 based on the research report published on May 18th of the previous year 2021.
Mizuho, on the other hand, stated in their research note that they expect to see CASI reach a price target of $3.80. The rating they have provided for CASI stocks is “Buy” according to the report published on April 26th, 2021.
Oppenheimer gave a rating of “Outperform” to CASI, setting the target price at $5 in the report published on October 23rd of the previous year.
CASI Trading at -14.70% from the 50-Day Moving Average
After a stumble in the market that brought CASI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -80.33% of loss for the given period.
Volatility was left at 7.81%, however, over the last 30 days, the volatility rate increased by 7.79%, as shares sank -4.32% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.25% lower at present.
During the last 5 trading sessions, CASI rose by +0.54%, which changed the moving average for the period of 200-days by -67.92% in comparison to the 20-day moving average, which settled at $0.8132. In addition, CASI Pharmaceuticals Inc. saw -4.11% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at CASI starting from He Wei-Wu, who purchase 200,000 shares at the price of $0.98 back on Nov 18. After this action, He Wei-Wu now owns 5,558,472 shares of CASI Pharmaceuticals Inc., valued at $196,000 using the latest closing price.
He Wei-Wu, the Chairman and CEO of CASI Pharmaceuticals Inc., purchase 200,000 shares at $0.99 during a trade that took place back on Nov 17, which means that He Wei-Wu is holding 5,362,569 shares at $198,000 based on the most recent closing price.
Stock Fundamentals for CASI
Current profitability levels for the company are sitting at:
- -223.01 for the present operating margin
- +27.30 for the gross margin
The net margin for CASI Pharmaceuticals Inc. stands at -321.89. The total capital return value is set at -33.02, while invested capital returns managed to touch -61.70. Equity return is now at value -49.90, with -32.50 for asset returns.
Based on CASI Pharmaceuticals Inc. (CASI), the company’s capital structure generated 3.92 points at debt to equity in total, while total debt to capital is 3.77. Total debt to assets is 2.50, with long-term debt to equity ratio resting at 1.18. Finally, the long-term debt to capital ratio is 1.14.
When we switch over and look at the enterprise to sales, we see a ratio of 1.70, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 5.05 and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.28.